Do­nat­ed glob­al­ly since 2005, No­var­tis' flat­worm treat­ment Egat­en wins FDA nod — and a PRV

No­var­tis $NVS has the fix for all your par­a­sitic flat­worm needs. The Swiss drug­mak­er de­vel­oped a hu­man treat­ment for fas­ci­o­lia­sis in part­ner­ship with the WHO af­ter for­mu­lat­ing a sim­i­lar med­i­cine for do­mes­tic live­stock who are al­so vul­ner­a­ble to the ne­glect­ed trop­i­cal dis­ease, which has cropped up in more than 70 coun­tries. Since 2005, the drug­mak­er has been do­nat­ing the drug — Egat­en — glob­al­ly, and on Wednes­day, the med­i­cine was ap­proved by the FDA.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.